Showing results (91-100 of 137) with videos related to

Sort By:
Pageof 14
Journal of Neurosurgery|April 4, 2015
Quantitative analysis of the Kawase versus the modified Dolenc-Kawase approach for middle cranial fossa lesions with variable anteroposterior extensionManjul Tripathi, Rama Chandra Deo, Ashish Suri, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2014
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitorsMark C Genovese, Maria Greenwald, Chul-Soo Cho, et al.
Environmental Toxicology and Pharmacology|January 6, 2009
Role of oxidative stress in the promoting activities of pcbsHoward P Glauert, Job C Tharappel, Zijing Lu, et al.
Toxicology and Applied Pharmacology|July 23, 2008
Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kappa B in miceHoward P Glauert, Job C Tharappel, Subhashis Banerjee, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Dual Lineage Tracing Identifies Cellular Mechanisms Underlying Radiation-Associated Changes in Atherosclerotic Lesion CompositionRebecca A Deaton, Tajbir Raihan, Victoria M Milosek, et al.
JAMA Dermatology|December 20, 2023
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical TrialKim A Papp, Kenneth Gordon, Bruce Strober, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
Journal of Lipid Research|April 13, 2012
The role of oxysterols in control of endothelial stiffnessTzu Pin Shentu, Dev K Singh, Myung-Jin Oh, et al.
The Journal of Allergy and Clinical Immunology|June 9, 2012
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasisJames G Krueger, Scott Fretzin, Mayte Suárez-Fariñas, et al.
The British Journal of Dermatology|October 22, 2024
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trialJianzhong Zhang, Yangfeng Ding, Ping Wang, et al.
Pageof 14